Merck Sues To Block Sandoz's Generic Zetia

Law360, New York (October 2, 2012, 7:53 PM EDT) -- Units of Merck & Co. Inc. on Thursday hit generics maker Sandoz Inc. with a patent infringement suit in New Jersey federal court in their latest effort to block generic versions of the anti-cholesterol drug Zetia.

Merck claims that Sandoz's generic version of Zetia, known chemically as ezetimibe, infringes four of its patents — U.S. Patent Numbers RE 42,461, 5,846,966, 7,030,106 and 7,612,058. The patents expire between 2014 and 2022, according to the complaint.

Sandoz notified Merck on Aug. 15 that it had submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration for generic ezetimibe, a cholesterol...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!